Seizure Disorders

Novel Vagus Nerve Stimulation Device Approved for Drug-Resistant Epilepsy

By October 10, 2017

The system includes a detect-and-respond mode, which is designed to prevent seizures before they start and deliver therapy to stop them if they do.

Antidepressant Overdose Risk Should Be Considered When Choosing Depression Tx

By September 26, 2017

Results showed that bupropion users were more likely to have a seizure, have accompanied tachycardia on presentation, and be admitted to the hospital, compared to those who ingested a TCA.

Briviact Approved as Monotherapy for Partial-Onset Seizures

By September 15, 2017

The sNDA submitted to support the monotherapy indication included clinical data involving over 2,400 adults with partial-onset seizures.

Aptiom Gains Expanded Pediatric Seizure Indication

By September 14, 2017

The efficacy and safety of Aptiom as monotherapy and adjunct therapy for adults with POS was previously established in 5 multicenter, randomized, controlled studies. This data also supported the safety and tolerability of Aptiom for the treatment of pediatric patients with POS.

Do Antiepileptic Treatments Affect Fetal Growth, Preterm Delivery?

September 11, 2017

Increased risk for women on AEDs for epilepsy or other indications; risk varies with drug used.

Does Antiepileptic Drug Use Contribute to Adverse Pregnancy Outcomes?

By August 14, 2017

Women with epilepsy were at increased risk of adverse pregnancy and delivery outcomes.

How Prevalent Is Epilepsy in the United States?

August 14, 2017

Increases in the number of persons with active epilepsy were indicated based on National Health Interview Survey data from 2010 to 2015, probably due to population growth.

Brexanolone Examined in Super-Refractory Status Epilepticus

August 09, 2017

The response end point of weaning successfully off TLAs before tapering brexanolone was met by 17 patients (77%).

Interactions Identified Between Cannabidiol, Antiepileptic Drugs

August 08, 2017

The researchers observed significant increases in topiramate, rufinamide, and N-desmethylclobazam and a significant decrease in clobazam serum levels with increasing cannabidiol dose.

Antiepileptic Drugs Compared for Partial Onset, Generalized Seizure Types

August 02, 2017

The researchers found that for individuals with partial seizures, levetiracetam performed statistically significantly better than carbamazepine and lamotrigine for time to withdrawal of allocated treatment.

Angioedema Risk Evaluated for Levetiracetam Versus Phenytoin

By July 25, 2017

"The results suggest that levetiracetam has the same or lower risk for angioedema than phenytoin," wrote the researchers.

Seizure Drug Discontinued Due to Limited Use

By July 11, 2017

Potiga, a potassium channel opener, was approved in 2011 as an adjunctive treatment for partial-onset seizures in patients with inadequate response to alternative treatments.

FDA Expands Age Range for VNS Device in Drug-Resistant Epilepsy

By June 29, 2017

Study patients reported a 50% reduction in seizure severity as well as an improvement in mood among 49% of patients. Improvements in memory and achievement were seen in 38% and 39% of patient, respectively. Moreover, patients reported a 64% reduction in seizure worry.

Novel Liquid Soln for Lennox Gastaut Syndrome Gets Orphan Drug Status

By June 22, 2017

The Company is awaiting top-line results of the current trial before initiating the LGS study.

Valproic Acid Monitoring Necessary with Ketogenic Diet

June 22, 2017

The researchers found that the serum concentrations of carbamazepine, lamotrigine, levetiracetam, topiramate, and valproic acid decreased after the dietary therapies.

Cannabidiol Oral Solution Studied in Drug-Resistant Seizures

By May 26, 2017

The data showed a reduction in the median frequency of convulsive seizure per month from 12.4 to 5.9 with cannabidiol vs. a reduction from 14.9 to 14.1 with placebo.

Fatal Outcome for Patient after Nasal Insufflation of Antidepressant

By May 22, 2017

A 45-year-old man with a past history of IV drug use was found to be insufflating bupropion at his rehabilitation facility.

Aptiom sNDA for Pediatric Indication Accepted for Review

By May 22, 2017

The sNDA submission includes data from five controlled clinical trials in adults with POS and three clinical studies demonstrating safety and tolerability in pediatric patients.

C.O. Truxton Expands Recall of Drugs with Possible Label Mix-Ups

By May 09, 2017

The C.O. Truxton product is packaged in 100- or 1000-count bottles in the following strengths: 15mg, 30mg, 60mg, and 100mg.

Undetected Seizures May Intensify Alzheimer's Pathology

May 03, 2017

One of the women experienced 3 seizures during a 12-hour period, with none producing any visible symptoms.

Intranasal Midazolam Evaluated as Rescue Therapy for Seizure Clusters

By May 02, 2017

Proximagen announced promising data from the pivotal Phase 3 trial of USL261 (intranasal midazolam) for the rescue treatment of seizure clusters. The primary efficacy endpoint was treatment success, defined as achieving 1) termination of seizure(s) and 2) no recurrence of seizure(s)

Social Outcomes Examined for Childhood-Onset Epilepsy

May 02, 2017

Those with uncomplicated epilepsy who were seizure-free for 5 years had social outcomes comparable to their siblings.

Guidelines on Sudden Unexpected Death in Epilepsy Released

By April 25, 2017

The greatest risk factor for SUDEP was found to be generalized tonic-clonic seizures (GTCS), with a higher frequency of these types of seizures correlating to an increased risk of death.

Intranasal Drug Delivery Increasingly Popular in the ER

April 24, 2017

Many benefits to nasal administration, including reduction in spread of infection

Mislabeled Phenobarbital Bottles Prompt Recall

By April 21, 2017

The mislabeled drug could lead to a potential overdose for patients or their pet(s), resulting in severe intoxication, cardiogenic shock, renal failure, coma or death.

AAN: Cannabidiol May Cut Seizures for Some LGS Patients

April 19, 2017

Cannabidiol appears to lessen drop seizures for some Lennox-Gastaut syndrome patients

Trokendi XR Gets Final FDA Approval for Migraine Prophylaxis

By April 06, 2017

In August 2016, the FDA granted tentative approval of the Company's one of two supplemental New Drug Applications (sNDAs). The final approval was contingent on the pediatric exclusivity of the drug in the adolescent population that expired March 28, 2017.

Qudexy XR Gains New Migraine Indication

By March 30, 2017

The FDA approved the sNDA's for Qudexy as prophylaxis of migraine headache in adults and children aged ≥12 years.

Dravet Syndrome Tx Receives Orphan Drug Status

By March 23, 2017

Currently, FDA approved treatments for this disorder are unavailable in the U.S.

Sunovion Seeks Pediatric Indication for Aptiom

By March 13, 2017

Aptiom, a dibenzazepine carboxamide antiepileptic, is currently approved for use as monotherapy or adjunctive therapy for partial onset seizures (POS) in adults, the new supplemental NDA aims to extend this indication for the treatment of POS in children aged ≥4 years.